The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia (Q36805830)
Jump to navigation
Jump to search
scientific article published on 12 October 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia |
scientific article published on 12 October 2012 |
Statements
1 reference
The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia (English)
1 reference
Dietger Niederwieser
1 reference
Thoralf Lange
1 reference
Thomas Ernst
1 reference
Franz X Gruber
1 reference
Jacqueline Maier
1 reference
Michael Cross
1 reference
Martin C Müller
1 reference
Markus Pfirrmann
1 reference
1 reference
1 reference
Identifiers
1 reference